Full text is available at the source.
Abstract
Multiplexed activation of genes led to enhanced anti-tumor responses in metastatic tumors.
- A CRISPR activation screen identified CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as key factors promoting anti-tumor immunity.
- The combination of TNFSF9 (4-1BBL), IFNG, and IL12B (4II) was found to be a potent therapeutic option.
- AAV-4II treatment improved antigen presentation, T cell activation, proliferation, cytotoxicity, and tumor infiltration.
- Preconditioning with AAV-4II enhanced the effectiveness of CAR-T and TCR-T cell therapies against solid tumors in vivo.
- TME-targeted CRISPRa screening may serve as a rapid approach to develop immune gene therapy combinations.
Simplified